Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Leinco Technologies Inc Anti-Mouse PD-1 (Programmed Death-1, CD279, PD 1) In Vivo GOLD; Clone 29F.1A12; Isotype: Rat IgG2a κ
SDP

Supplier:  Leinco Technologies Inc P37725 MG

Encompass_Preferred

Specificity: Clone 29F.1A12 recognizes an epitope on mouse PD-1. Antigen distribution: PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells. Background: PD-1 is a 50-55 kD member of the Ig superfamily and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 (B7-H1) and PD-L2 (B7-DC). The ligands are members of the B7 Ig superfamily. Applications: (WB, B) Similar to clones RMP1-14 and J43, clone 29F.1A12 has been shown to block the binding of PD-1 to its ligands In vivo. Leinco’s In vivo GOLDTM and In vivo PLATINUMTM functional antibodies are manufactured in an animal free facility using only In vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Catalog No. 50-190-6587


May include imposed supplier surcharges.
Only null left
Add to Cart

Product Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.